|
Nov. 5, 2001 Landmark Smallpox Vaccine Study Underway; Volunteers
Still Needed
The University of Rochester Medical Center is one of four institutions
nationwide that the Federal government has turned to in an effort
to increase the number of available doses from existing stocks of
smallpox vaccine. The research study is part of an effort by the U.S.
government to extend the supply of the vaccine in case the deadly
virus is released as part of a bioterrorism attack. The nation has
about 15 million doses on hand; millions more are being made by pharmaceutical
firms but are not yet available. Approximately 200 individuals in the Rochester area who have never
been vaccinated will participate in the research study at Strong Memorial
Hospital, part of a total of 684 healthy individuals who are participating
nationwide. The vaccine contains no smallpox virus, and doctors stress that
there is no risk of developing smallpox from the vaccine. Indeed,
prior to 1972, getting the vaccine was regarded as a harmless rite
of passage: Schoolchildren received the vaccine, then went back to
the classroom the same day and compared scabs later in the week. The
dime-sized scar that nearly all U.S. citizens older than 32 carry
on their upper arms or elsewhere on the body is proof that they received
the vaccine as a child. The vaccine is the same one used as part of
a worldwide immunization program that eradicated smallpox everywhere
but in research laboratories by 1979, an effort led by Rochester alumnus
D.A. Henderson. Study participants are receiving the traditional smallpox vaccine
or a diluted form of the vaccine, either one-fifth or one-tenth the
traditional dose. Vaccine expert John Treanor, M.D., associate professor
of medicine and the leader of the Rochester portion of the study,
says the clearest sign of successful vaccination will be the development
of a dime-sized blister where the injection is given. The blister
will scab over and heal within a few weeks, leaving a well recognized
scar. After the initial immunization, patients will be seen every three
or four days for at least two weeks as nurses check the condition
of the blister or scab and change the bandage. The study will last
about two months. Though more than 400 people have called to ask about taking part
in the study, many more volunteers are still needed, says Treanor. Anyone interested in volunteering must be in good health, between
the ages of 18 and 32, and must never have been vaccinated against
smallpox. Volunteers also cannot have eczema or a condition that weakens
the immune system. Prospective participants are excluded if they have
daily close contact with a woman who is pregnant or with children
under one year of age. Women who are pregnant or breastfeeding are
not eligible. Participants who qualify will be paid $25 per visit, with eight
visits scheduled, and parking will be free. Anyone interested in volunteering for the study should call (716)
273-3990. Other institutions taking part in the study are Saint Louis University,
Baylor College of Medicine, and the University of Maryland. The group
comprises a network of research centers funded by the National Institutes
of Health to develop and test new vaccines for a variety of illnesses,
including flu, pneumonia, rotavirus, and whooping cough. The current
study focusing on the effectiveness of a diluted form of smallpox
vaccine is very similar to a study carried out by the researchers
last year on a flu vaccine.
| ||
©Copyright University of Rochester Medical Center, 1999-2006. Disclaimer. For questions or suggestions concerning the content of these pages, contact the URMC Webmaster. | ||